A pact with Dermelix Biotherapeutics to co-develop a cure for a rare pediatric genetic disease promises to generate vital funds for advancing EspeRare’s venture philanthropic model to tackle unmet life-threatening medical needs affecting children, the non-profit foundation’s CEO told Scrip.
Caroline Kant made the comments during an interview outlining EspeRare's pact with privately held Dermelix for co-development of the Swiss...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?